4D pharma appoints John Doyle as Chief Financial Officer

Author's Avatar
Jan 03, 2022

4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the appointment of John Doyle as Chief Financial Officer (CFO). Mr. Doyle brings over 15 years of experience leading and developing the financial operations, strategy and investor relations functions at public healthcare companies.